ClinicalTrials.gg
CompletedNCT01070043Updated Oct 19, 2011Results posted

To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone

A Phase 4 interventional study of Amlodipine 5mg/Valsartan 80 mg and Valsartan in Hypertension and High Blood Pressure, sponsored by Novartis. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-19.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
146th of 186
60 · median 180
Started
2009
with 12 others
Phase 4
80 of 187
2 open now
Registered
88th of 187
by date
Lead sponsor
40 of 187
Novartis

Among the 187 studies testing amlodipine in Hypertension, this one is the 146th largest by enrollment of the 186 interventional ones that give a count, is one of 13 that started in 2009, is one of 80 in phase 4, and was the 88th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The purpose of the study was to assess efficacy and safety of fixed dose combination of 5 mg amlodipine/80 mg valsartan compared to 160 mg valsartan monotherapy in lowering blood pressure in Taiwanese patients.

03

Conditions studied

  • Hypertension
  • High Blood Pressure

Browse trials for

Keywords

  • Hypertension
  • valsartan
  • amlodipine
  • high blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants over 18 years of age with hypertension defined as sitting systolic blood pressure between 140 mmHg and 180 mmHg or sitting diastolic blood pressure between 90 mmHg and 120 mmHg.
  • High risk participants ( defined as having: (diabetes mellitus, chronic renal disease, Framingham 10-year risk score >10%, established coronary artery disease (CAD), or CAD equivalents including carotid artery disease, peripheral arterial disease (PAD), abdominal aortic aneurysm (AAA))with hypertension defined as sitting systolic blood pressure between 130 mmHg and 180 mmHg or sitting diastolic blood pressure between 80 mmHg and 120 mmHg.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected secondary hypertension
  • Known (NYHA) functional class IV Heart Failure
  • History of myocardial infarction, or cerebrovascular accident within the preceding 3 months
  • valvular disease
  • Women who are pregnant, intend to become pregnant or are breastfeeding
  • Participants who have severe medical condition(s) that in the view of the Investigator prohibits participation in the study
  • Participants who have to the / reference drug or any of the components in the formulation.
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Amlodipine 5mg/Valsartan 80 mg

    During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.

    Drug: Amlodipine 5mg/Valsartan 80 mg

  • Active comparator
    Valsartan 160 mg

    In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.

    Drug: Valsartan

  • Other
    Run-In Valsartan 80 mg

    During run-in period, oral valsartan 80 mg once daily for 4 weeks.

    Drug: Valsartan

Interventions

  • DrugAmlodipine 5mg/Valsartan 80 mg

    Drug page: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.

    Also known as: Exforge

  • For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks. Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks

    Also known as: Diovan

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement

    Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting systolic blood pressure (msSBP) was calculated comparing the Week 8 readings to the readings taken at baseline.

    Time frame: Baseline and 8 weeks

  2. Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement

    Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting diastolic blood pressure (msDBP) was calculated comparing the Week 8 readings to the readings taken at Baseline.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours

    Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean systolic blood pressure (mSBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind phase.

    Time frame: Baseline and 8 weeks

  2. Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase

    Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean diastolic blood pressure (mDBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind.

    Time frame: Baseline and 8 weeks

  3. Number of Participants With Adverse Events During Double-blind Phase

    Time frame: 8 weeks

07

Results

Posted Oct 19, 2011

Participant flow

Run-In Phase
Participant flow — Run-In Phase
MilestoneRun-In Valsartan 80 mgAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Started6000
Completed4200
Not completed1800
Withdrew: Did not meet inclusion criteria1800
Double-Blind Treatment
Participant flow — Double-Blind Treatment
MilestoneRun-In Valsartan 80 mgAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Started02121
Completed02119
Not completed002
Withdrew: Adverse event002

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement

Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting systolic blood pressure (msSBP) was calculated comparing the Week 8 readings to the readings taken at baseline.

Time frame:
Baseline and 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement
mmHgAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Baseline150.26 ± 12.91141.14 ± 12.71
8 weeks133.79 ± 14.63133.68 ± 12.73
Change from baseline to 8 weeks-16.48 ± 15.53-7.23 ± 11.60
PrimaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement

Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting diastolic blood pressure (msDBP) was calculated comparing the Week 8 readings to the readings taken at Baseline.

Time frame:
Baseline and 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement
mmHgAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Baseline92.12 ± 10.8489.98 ± 9.37
8 weeks82.29 ± 8.7486.73 ± 9.10
Change from baseline to 8 weeks-9.83 ± 7.66-2.65 ± 6.75
SecondaryChange From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours

Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean systolic blood pressure (mSBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind phase.

Time frame:
Baseline and 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours
mmHgAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Baseline144.38 ± 17.39139.76 ± 13.46
8 weeks129.67 ± 14.03131.11 ± 12.39
Change from baseline to 8 weeks-14.71 ± 11.64-6.39 ± 12.06
SecondaryChange From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase

Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean diastolic blood pressure (mDBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind.

Time frame:
Baseline and 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase
mmHgAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Baseline86.95 ± 14.1487.90 ± 9.44
8 weeks79.29 ± 10.7082.94 ± 8.42
Change from baseline to 8 weeks-7.67 ± 7.43-3.56 ± 7.70
SecondaryNumber of Participants With Adverse Events During Double-blind Phase
Time frame:
8 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events During Double-blind Phase
ParticipantsAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Total AE915
At least one AE711
AE Not related to drug915

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine 5 mg/Valsartan 80 mg—0/21 (0%)6/21 (28.6%)
Valsartan 160 mg—1/21 (4.8%)8/21 (38.1%)
Most frequent serious events
Most frequent serious events
EventAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/211/21
Most frequent other events
Most frequent other events
EventAmlodipine 5 mg/Valsartan 80 mgValsartan 160 mg
Upper respiratory tract infectionInfections and infestations2/213/21
DizzinessNervous system disorders0/212/21
HeadacheNervous system disorders2/211/21
CoughRespiratory, thoracic and mediastinal disorders2/212/21

Baseline characteristics

Age Continuous
Age Continuous(years)Amlodipine 5mg/Valsartan 80 mgValsartan 160 mgTotal
Mean59.50 ± 13.8155.13 ± 11.8157.31 ± 13.81
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine 5mg/Valsartan 80 mgValsartan 160 mgTotal
Female9817
Male121325
08

Study locations

1 site
  • Taipei, 11217, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2010
First posted
Feb 17, 2010
Start
Jun 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Oct 19, 2011
Last update
Oct 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01070043
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Feb 17, 2010
Start date
Jun 2009
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Oct 19, 2011
Last update
Oct 19, 2011

Study contacts

Novartis Novartis
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion